High ATR expression in tumours showed an adverse clinical outcome with poor ovarian cancer specific survival (p = 0.001) (Fig. 2g) and progression free survival (p = 0.008) (Fig. 2h) compared with tumours that had low ATR expression. This evidence concerns the gene ATR and ovarian carcinoma.